12.15.14 The development of renewable capture reagents that could be produced more efficiently and cost-effectively than monoclonal antibodies is a key topic in diagnostics and therapeutics. The cancer research community has demonstrated a critical need for these reagents for biomarker detection. In collaboration with the National Cancer Institute’s Office of Cancer Clinical Proteomics Research, Base Pair Biotechnologies has developed anti-peptide capture reagents that can be used to identify and quantify proteins containing a specific target peptide sequence and specific modification. Such reagents could be extremely useful in biomarker validations using powerful technologies, such as Stable Isotope Standard Capture with Anti-Peptide Anti-bodies (SISCAPA) in conjunction with Multi-Reaction Monitoring Mass Spectrometry (MRM-MS). The scientists at Base Pair Biotechnologies have developed high-affinity aptamers against specific phosphorylated and unmodified peptide target sequences of certain cancer biomarkers of interest by utilizing a patented, multiplexed “Systematic Evolution of Ligands by Exponential enrichment” (SELEX) approach.